FDA escalates recall of blood pressure drug over carcinogen concerns - Another Big Pharma Failure
Over 112,000 bottles of a top-prescribed beta-blocker now carry moderate risk classification, exposing cracks in generic manufacturing reliability right when patients need steady heart support most.
